- Home
- Publications
- Publication Search
- Publication Details
Title
Novel therapeutic targets for cholestatic and fatty liver disease
Authors
Keywords
-
Journal
GUT
Volume 71, Issue 1, Pages 194-209
Publisher
BMJ
Online
2021-10-22
DOI
10.1136/gutjnl-2021-324305
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
- (2021) Jörn M. Schattenberg et al. JOURNAL OF HEPATOLOGY
- A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Real-World Clinical Management of Patients with Primary Biliary Cholangitis—A Retrospective Multicenter Study from Germany
- (2021) Anne-Christin Beatrice Wilde et al. Journal of Clinical Medicine
- Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial
- (2021) Samer Gawrieh et al. HEPATOLOGY
- Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis
- (2021) Maria Reich et al. JOURNAL OF HEPATOLOGY
- A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis
- (2021) Raj Vuppalanchi et al. Clinical and Translational Gastroenterology
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges
- (2020) Sander Lefere et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities
- (2020) Benjamin Goeppert et al. HEPATOLOGY
- Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
- (2020) Vlad Ratziu et al. HEPATOLOGY
- Monocytes as potential mediators of pathogen‐induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC)
- (2020) Lilly Kristin Kunzmann et al. HEPATOLOGY
- Thyroid hormones and thyromimetics: A new approach to NASH?
- (2020) Rohit Anthony Sinha et al. HEPATOLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
- (2020) Jean-François Dufour et al. GUT
- Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis
- (2020) Wei Chen et al. HEPATOLOGY
- The role of metabolic lipases in the pathogenesis and management of liver disease
- (2020) Matteo Tardelli et al. HEPATOLOGY
- Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities
- (2020) Mette Vesterhus et al. JOURNAL OF GASTROENTEROLOGY
- A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
- (2020) Kris V. Kowdley et al. JOURNAL OF HEPATOLOGY
- Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
- (2020) Philip N. Newsome et al. JOURNAL OF HEPATOLOGY
- Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults
- (2020) Albert Friedrich Stättermayer et al. JOURNAL OF HEPATOLOGY
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis
- (2020) Yevgeniy Gindin et al. HEPATOLOGY
- Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders
- (2020) Saul J. Karpen et al. Hepatology International
- Design and Structural Optimization of Dual FXR/PPARδ Activators
- (2020) Simone Schierle et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases
- (2020) Massimiliano Cadamuro et al. Frontiers in Medicine
- Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double blind, randomized, placebo-controlled trial
- (2020) Elsemieke de Vries et al. GASTROENTEROLOGY
- The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis
- (2020) Rohit Loomba et al. HEPATOLOGY
- A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA
- (2020) G.M. Hirschfield et al. JOURNAL OF HEPATOLOGY
- Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
- (2020) Sven Francque et al. Nature Reviews Gastroenterology & Hepatology
- Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
- (2020) Stefan Traussnigg et al. WIENER KLINISCHE WOCHENSCHRIFT
- Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
- (2020) Zoe Boyer-Diaz et al. JOURNAL OF HEPATOLOGY
- FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
- (2020) Erik J. Tillman et al. Frontiers in Endocrinology
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate
- (2020) Lena Smets et al. HEPATOLOGY
- The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC
- (2019) Michael Trauner et al. HEPATOLOGY
- Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis
- (2019) Nobuhiro Nakamoto et al. Nature Microbiology
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis
- (2019) Akira Honda et al. HEPATOLOGY
- Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis
- (2019) Jessica R. Allegretti et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Cholangiocyte‐Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis
- (2019) Runping Liu et al. HEPATOLOGY
- The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
- (2019) Arun J. Sanyal et al. HEPATOLOGY
- LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
- (2019) Rohit Loomba et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study
- (2019) John E. Eaton et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice
- (2019) Daniel Lindén et al. Molecular Metabolism
- Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
- (2019) Jonathan D. Roth et al. Scientific Reports
- FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
- (2019) Aroosha Raja et al. Cells
- Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
- (2019) Michael Trauner et al. Lancet Gastroenterology & Hepatology
- Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
- (2019) Stefan Traussnigg et al. Lancet Gastroenterology & Hepatology
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
- (2019) Rohit A. Sinha et al. THYROID
- Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis
- (2019) Christopher L. Bowlus et al. Clinical Gastroenterology and Hepatology
- Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends
- (2019) Lixia Gao et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies
- (2019) Marica Meroni et al. Nutrients
- Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae
- (2019) Jing Yuan et al. Cell Metabolism
- New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases
- (2019) Sara Lemoinne et al. CURRENT OPINION IN PHARMACOLOGY
- The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis
- (2019) Maria Eugenia Guicciardi et al. HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression
- (2019) Fabián Segovia-Miranda et al. NATURE MEDICINE
- Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis
- (2018) J. L. Damman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
- (2018) Juan Pablo Arab et al. Annual Review of Pathology-Mechanisms of Disease
- Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists
- (2018) Gwilym James Webb et al. Clinical Gastroenterology and Hepatology
- Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis
- (2018) Donghee Kim et al. Clinical Gastroenterology and Hepatology
- The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease
- (2018) Puneet Puri et al. Clinics in Liver Disease
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Colesevelam attenuates cholestatic liver and bile duct injury inMdr2−/−mice by modulating composition, signalling and excretion of faecal bile acids
- (2018) Claudia Daniela Fuchs et al. GUT
- Na+ -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice
- (2018) Davor Slijepcevic et al. HEPATOLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
- (2018) Kris V. Kowdley et al. HEPATOLOGY
- Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD
- (2018) Eveline Bruinstroop et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study
- (2018) C. Schramm et al. JOURNAL OF HEPATOLOGY
- Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice
- (2018) Maria Eugenia Guicciardi et al. JOURNAL OF HEPATOLOGY
- Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis
- (2018) Marion J. Pollheimer et al. JOURNAL OF HEPATOLOGY
- FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
- (2018) Romeo Papazyan et al. JOURNAL OF LIPID RESEARCH
- Thyroid hormone receptor β1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice
- (2018) Julien Gautherot et al. JOURNAL OF LIPID RESEARCH
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK
- (2018) Roger Williams et al. LANCET
- Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents
- (2018) Dongke Yu et al. LIVER INTERNATIONAL
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
- (2018) Christophe Corpechot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide
- (2018) Manabu Kaneko et al. Scientific Reports
- Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease
- (2018) Andrew J. Muir et al. HEPATOLOGY
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
- (2018) Maurizio Parola et al. MOLECULAR ASPECTS OF MEDICINE
- Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
- (2018) T. D. Müller et al. PHARMACOLOGICAL REVIEWS
- PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC
- (2018) Beata Kruk et al. PLoS One
- Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French–Spanish experience
- (2018) Sara Lemoinne et al. Clinics and Research in Hepatology and Gastroenterology
- FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid
- (2018) Elliot S. Friedman et al. GASTROENTEROLOGY
- The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor
- (2018) Yi Liu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
- (2018) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
- (2018) Gideon M. Hirschfield et al. JOURNAL OF HEPATOLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Role of TGR5 (GPBAR1) in Liver Disease
- (2018) Dieter Häussinger et al. SEMINARS IN LIVER DISEASE
- Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis
- (2018) Raffaella Maria Gadaleta et al. Scientific Reports
- Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
- (2017) Oscar Chávez-Talavera et al. GASTROENTEROLOGY
- Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy
- (2017) Ruqi Tang et al. GUT
- Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
- (2017) Na Jiao et al. GUT
- The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells
- (2017) Francesca Virginia Bruschi et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- New therapeutic concepts in bile acid transport and signaling for management of cholestasis
- (2017) Michael Trauner et al. HEPATOLOGY
- The ascending pathophysiology of cholestatic liver disease
- (2017) Peter L.M. Jansen et al. HEPATOLOGY
- Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects
- (2017) Vanessa Legry et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Distinct but complementary contributions of PPAR isotypes to energy homeostasis
- (2017) Vanessa Dubois et al. JOURNAL OF CLINICAL INVESTIGATION
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
- (2017) Gideon M. Hirschfield et al. JOURNAL OF HEPATOLOGY
- nor Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
- (2017) Peter Fickert et al. JOURNAL OF HEPATOLOGY
- Primary sclerosing cholangitis – a comprehensive review
- (2017) Tom H. Karlsen et al. JOURNAL OF HEPATOLOGY
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
- (2017) Valerio Nobili et al. LIVER INTERNATIONAL
- Inflammation, metaflammation and immunometabolic disorders
- (2017) Gökhan S. Hotamisligil NATURE
- Mechanisms of hepatic stellate cell activation
- (2017) Takuma Tsuchida et al. Nature Reviews Gastroenterology & Hepatology
- The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts
- (2017) Johannes Hov et al. SEMINARS IN LIVER DISEASE
- Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP
- (2017) Joanne M. Donkers et al. Scientific Reports
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers
- (2016) Annarosa Floreani et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?
- (2016) Swetha Rudraiah et al. Annual Review of Pharmacology and Toxicology
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
- (2016) Frank J. Gonzalez et al. GASTROENTEROLOGY
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- Hepatitis B virus receptors and molecular drug targets
- (2016) Eloi R. Verrier et al. Hepatology International
- Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis
- (2016) Anna Baghdasaryan et al. JOURNAL OF HEPATOLOGY
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
- (2016) Petra Hirsova et al. JOURNAL OF LIPID RESEARCH
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
- (2016) Frederik Nevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice
- (2016) Anuradha Rao et al. Science Translational Medicine
- Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid
- (2016) Christophe Corpechot SEMINARS IN LIVER DISEASE
- Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease
- (2016) Claudia Fuchs et al. SEMINARS IN LIVER DISEASE
- Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
- (2016) Natalia Gomez-Ospina et al. Nature Communications
- Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes
- (2015) A. C. Cheung et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Homeostasis, Inflammation, and Disease Susceptibility
- (2015) Maya E. Kotas et al. CELL
- Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice
- (2015) Magdalena Mazagova et al. FASEB JOURNAL
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
- (2015) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis
- (2015) James H. Tabibian et al. HEPATOLOGY
- Fibrates and cholestasis
- (2015) Nisanne S. Ghonem et al. HEPATOLOGY
- Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice
- (2015) Alexander G. Miethke et al. HEPATOLOGY
- Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na+-taurocholate cotransporting polypeptide knockout mice
- (2015) Davor Slijepcevic et al. HEPATOLOGY
- Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2 -deficient mice
- (2015) Mei Zhou et al. HEPATOLOGY
- Genetics of liver disease: From pathophysiology to clinical practice
- (2015) Tom H. Karlsen et al. JOURNAL OF HEPATOLOGY
- Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
- (2015) Michaela Mueller et al. JOURNAL OF HEPATOLOGY
- New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond
- (2015) Ulrich Beuers et al. JOURNAL OF HEPATOLOGY
- Hepatic fibrosis: Concept to treatment
- (2015) Christian Trautwein et al. JOURNAL OF HEPATOLOGY
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Large-scale whole-genome sequencing of the Icelandic population
- (2015) Daniel F Gudbjartsson et al. NATURE GENETICS
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
- (2015) Sungsoon Fang et al. NATURE MEDICINE
- Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
- (2015) Chiara Degirolamo et al. NATURE REVIEWS DRUG DISCOVERY
- Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
- (2015) Changtao Jiang et al. Nature Communications
- Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis
- (2015) Alla Y. Grigorian et al. Clinics and Research in Hepatology and Gastroenterology
- Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
- (2014) M. Zhou et al. CANCER RESEARCH
- Interactions Between the Intestinal Microbiome and Liver Diseases
- (2014) Bernd Schnabl et al. GASTROENTEROLOGY
- Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype
- (2014) Frédéric M. Vaz et al. HEPATOLOGY
- Saturated free fatty acids induce cholangiocyte lipoapoptosis
- (2014) Sathish Kumar Natarajan et al. HEPATOLOGY
- A nontumorigenic variant of FGF19 treats cholestatic liver diseases
- (2014) J. Luo et al. Science Translational Medicine
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
- (2013) Shin Yoshimoto et al. NATURE
- A Frequent PNPLA3 Variant Is a Sex Specific Disease Modifier in PSC Patients with Bile Duct Stenosis
- (2013) Kilian Friedrich et al. PLoS One
- Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome
- (2012) Anne Vrieze et al. GASTROENTEROLOGY
- TGR5 potentiates GLP-1 secretion in response to anionic exchange resins
- (2012) Taoufiq Harach et al. Scientific Reports
- Identical Gene Regulation Patterns of T3and Selective Thyroid Hormone Receptor Modulator GC-1
- (2011) Chaoshen Yuan et al. ENDOCRINOLOGY
- Alterations in Lipid Metabolism Mediate Inflammation, Fibrosis, and Proliferation in a Mouse Model of Chronic Cholestatic Liver Injury
- (2011) Tarek Moustafa et al. GASTROENTEROLOGY
- Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA
- (2011) S. Fiorucci et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus
- (2010) Andreas E. Kremer et al. GASTROENTEROLOGY
- Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches
- (2010) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation
- (2010) A. Baghdasaryan et al. GUT
- Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues
- (2010) Vlad Ratziu et al. HEPATOLOGY
- High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial
- (2010) Ulrich F. H. Leuschner et al. HEPATOLOGY
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites
- (2010) Brent A. Neuschwander-Tetri HEPATOLOGY
- The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation
- (2010) Thijs W.H. Pols et al. JOURNAL OF HEPATOLOGY
- A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
- (2010) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nuclear receptors as therapeutic targets in cholestatic liver diseases
- (2009) Gernot Zollner et al. BRITISH JOURNAL OF PHARMACOLOGY
- Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice
- (2009) Emina Halilbasic et al. HEPATOLOGY
- Hepatocyte-specific NEMO deletion promotes NK/NKT cell– and TRAIL-dependent liver damage
- (2009) Naiara Beraza et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The new therapeutic frontier – Nuclear receptors and the liver
- (2009) Saul J. Karpen et al. JOURNAL OF HEPATOLOGY
- Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease
- (2009) Marina G. Silveira et al. LIVER INTERNATIONAL
- Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
- (2009) Philippe Lefebvre et al. PHYSIOLOGICAL REVIEWS
- Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study
- (2008) Frank P. Vleggaar et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis
- (2008) M Marzioni et al. GUT
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
- (2008) Stefano Romeo et al. NATURE GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now